Background: There is a growing interest in the use of cannabis (and its extracts), as well as
CBD oil (hemp extracts containing cannabidiol), for therapeutic purposes. While there is …

There is increasing interest in the use of cannabinoids for disease and symptom
management, but limited information available regarding their pharmacokinetics and …

The interest in cannabis-based products for the treatment of refractory epilepsy has
skyrocketed in recent years. Marijuana and other cannabis products with high content in Δ …

Novel and effective antiseizure medications are needed to treat refractory and rare forms of
epilepsy. Cannabinoids, which are obtained from the cannabis plant, have a long history of …

Although the medicinal properties of Cannabis species have been known for centuries, the
interest on its main active secondary metabolites as therapeutic alternatives for several …

Cannabidiol (CBD) is a major active component of the Cannabis plant, which, unlike
tetrahydrocannabinol (THC), is devoid of euphoria-inducing properties. During the last 10 …

In the past two decades, there has been an increasing interest in the therapeutic potential of
cannabinoids for neurological disorders such as epilepsy, multiple sclerosis, pain, and …

This article provides a critical appraisal of the available evidence concerning clinical
exposure to orally administered cannabidiol (CBD), with special reference to factors …

The first plant-derived, purified pharmaceutical-grade cannabidiol (CBD) medication,
Epidiolex, was approved in the United States by the FDA on June 25, 2018. Its approval for …

Cannabis is the most used illicit drug worldwide and its medicinal use is under discussion,
being regulated in several countries. However, the psychotropic effects of Δ 9 …